16:10 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; lung cancer Cell culture studies identified a triple KRAS/NRAS/HRAS inhibitor that could help treat KRAS-mutant colorectal cancer and NRAS-mutant non-small cell lung cancer (NSCLC). Screening of a small molecule library, structure-based optimization of...
22:49 , Aug 10, 2018 |  BC Extra  |  Preclinical News

New approach could identify Ras-blocking small molecules

With an eye on historically undruggable cancer target Ras, a University of Oxford team and colleagues devised a way to find small molecules that have the same qualities as Ras inhibitors too large to access...
21:35 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma, colorectal cancer In vitro, cell culture and mouse studies identified an aminopyrimidine-based dual MAPK1/MAPK3 inhibitor that could help treat BRAF-mutant melanoma and colorectal cancer. Fragment-based screening, chemical synthesis and in vitro enzyme activity...
16:49 , Jun 21, 2018 |  BC Innovations  |  Translation in Brief

PHIP the script

Cancers lacking key molecular signatures targeted by precision therapies are among the most challenging to treat, but a new study has identified a target, PHIP, for three of those difficult tumor types. A group led...
18:21 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer In vitro and cell culture studies identified a quindoline-based stabilizer of the NRAS mRNA G-quadruplex region that could help treat cancer. Chemical synthesis and in vitro testing in binding and enzyme activity assays of...
23:15 , Mar 20, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs; Plasma markers A plasma cfDNA mutation on PI3KCA could help predict resistance to combined inhibition of MEK, CDK4 and CDK6 in NRAS-mutant melanoma. In samples from a patient with metastatic NRAS-mutant melanoma treated with...
22:30 , Jan 4, 2018 |  BC Innovations  |  Strategy

Next generation resolutions

With a slew of landmark approvals in the last 18 months, FDA has solidified its commitment to advancing genetic diagnostics. Now the agency is turning to the outstanding challenges, with solutions on the horizon for...
00:18 , Aug 18, 2017 |  BC Innovations  |  Translation in Brief

Next-generation growth spurt

A milestone FDA approval could signal next-generation sequencing tests are on the verge of becoming established players in cancer diagnostics. A series of papers published this week highlights further advances in NGS technology, but the...
14:43 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

FDA approves Amgen's sBLA for Vectibix in mCRC

Amgen Inc. (NASDAQ:AMGN) said FDA approved an sBLA for Vectibix panitumumab to treat wild-type Ras metastatic colorectal cancer (mCRC), defined as wild-type in both K-Ras (KRAS) and neuroblastoma Ras viral (v-Ras) oncogene (NRAS) as determined...
21:00 , Jun 22, 2017 |  BC Innovations  |  Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...